Regeneron Pharmaceuticals...

NASDAQ: REGN · Real-Time Price · USD
580.43
14.46 (2.55%)
At close: Aug 15, 2025, 3:59 PM
580.30
-0.02%
After-hours: Aug 15, 2025, 04:13 PM EDT

Regeneron Pharmaceuticals Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
3.68B 3.03B 3.79B 3.72B 3.55B 3.15B 3.43B 3.36B 3.16B 3.16B 3.41B 2.94B 2.86B 2.97B 4.95B 3.45B 5.14B 2.53B
Cost of Revenue
665.3M 591.2M 691.5M 612.8M 600.9M 547.9M 629.1M 541.8M 508M 557M 507M 410.4M 371.5M 479.2M 1.06B 526.4M 764.8M 375.4M
Gross Profit
3.01B 2.44B 3.1B 3.11B 2.95B 2.6B 2.81B 2.82B 2.65B 2.61B 2.91B 2.53B 2.49B 2.49B 3.89B 2.93B 4.37B 2.15B
Operating Income
1.09B 604M 1.03B 1.24B 1.09B 758.5M 1.05B 1.21B 1.02B 1B 1.32B 1.22B 1.31B 1.29B 2.64B 1.85B 3.35B 1.11B
Interest Income
174.8M 173.5M 183.1M 187.4M 179.4M 161.5M 148.7M 133.7M 118.3M n/a n/a n/a n/a n/a n/a n/a n/a n/a
Pretax Income
1.52B 905M 958.1M 1.49B 1.63B 700.7M 1.15B 1.11B 1.08B 858M 1.32B 1.51B 963.2M 1.06B 2.5B 1.82B 3.75B 1.25B
Net Income
1.39B 808.7M 917.7M 1.34B 1.43B 722M 1.16B 1.01B 968.4M 817.8M 1.2B 1.32B 852.1M 973.5M 2.23B 1.63B 3.1B 1.12B
Selling & General & Admin
634.2M 633M 783.7M 714.4M 758.8M 689M 704.4M 640.5M 652M 601.1M 657M 529.1M 476.3M 450M 559.6M 445M 414.7M 405.6M
Research & Development
1.29B 1.2B 1.27B 1.15B 1.08B 1.13B 1.05B 969.9M 982.2M 1B 941.6M 818.7M 719.9M 769.5M 711.1M 592.2M 643.1M 675.5M
Other Expenses
n/a n/a 15.5M 8M 14.6M 15.3M -500K -500K -600K -500K -6.6M -45.7M -17.4M -20.2M -15.8M 42M -31.3M -40.5M
Operating Expenses
1.92B 1.83B 2.07B 1.87B 1.85B 1.84B 1.75B 1.61B 1.63B 1.6B 1.59B 1.3B 1.18B 1.2B 1.25B 1.08B 1.03B 1.04B
Interest Expense
3.6M 8.7M 10.5M 13.8M 14.8M 16.1M 18.3M 17.8M 18.9M 18M 17.4M 15.3M 13.1M 13.6M 14.1M 14.2M 14.4M 14.6M
Selling & Marketing Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
2.59B 2.42B 2.76B 2.48B 2.45B 2.39B 2.38B 2.15B 2.14B 2.16B 2.1B 1.71B 1.55B 1.68B 2.31B 1.61B 1.79B 1.42B
Income Tax Expense
127.1M 96.3M 40.4M 152.4M 195.8M -21.3M -12M 103M 114.5M 40.2M 127.6M 194.1M 111.1M 87.6M 274.4M 184.4M 653.9M 137.8M
Shares Outstanding (Basic)
105.1M 106.7M 107.9M 108.1M 108.1M 107.8M 106.6M 106.3M 107M 107.1M 107M 112.8M 114M 113.07M 106.2M 106.2M 105M 110.5M
Shares Outstanding (Diluted)
108.6M 111.2M 113.8M 116.2M 115.4M 115.1M 113.8M 113.4M 113.9M 114M 114M 112.8M 114M 113.1M 113.2M 113.9M 110.8M 110.53M
EPS (Basic)
13.24 7.58 8.53 12.40 13.25 6.70 10.88 9.48 9.05 7.64 11.19 11.66 7.47 8.61 20.99 15.37 29.51 10.58
EPS (Diluted)
12.81 7.27 8.06 11.54 12.41 6.27 10.19 8.89 8.50 7.17 10.50 11.66 7.47 8.61 19.69 14.33 27.97 10.09
EBITDA
1.66B 1.04B 1.09B 1.63B 1.76B 830.9M 1.28B 1.23B 1.2B 975.5M 1.44B 1.62B 1.05B 1.15B 2.59B 1.9B 3.84B 1.33B
EBIT
1.52B 913.7M 968.6M 1.51B 1.64B 716.8M 1.17B 1.13B 1.1B 876M 1.34B 1.53B 976.3M 1.07B 2.52B 1.83B 3.77B 1.27B
Depreciation & Amortization
135.1M 126.9M 126.4M 121.7M 120.7M 114.1M 113M 105.4M 103.1M 99.5M 100.1M 92.6M 74.4M 74.3M 74.5M 73.2M 71.1M 67.4M